Why are some people better at processing sounds?
St. Jude scientists identified the mechanism that gives Williams-Beuren Syndrome patients enhanced ability to discriminate between sounds as interneuron hyperexcitability in the auditory cortex.
Where does medulloblastoma come from?
St. Jude scientists found that group 3 and 4 medulloblastoma arise from the rhombic lip, which may help improve research models and therapeutic development.
What doesn’t kill cancer can make it stronger
St. Jude researchers discovered how some cancer cells survive treatment and cause cancer to recur, along with a way to stop the process.
An ounce of DNA is worth pounds of prevention in cancer survivors
St. Jude scientists found that childhood cancer survivors are at risk of obesity. They wanted a tool to identify survivors likely to become severely or “morbidly” obese as adults.
Improving memory problems in CAR T cells
St. Jude scientists identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model.
Heterochromatin silencing is like a piano that doesn’t make a sound
St. Jude scientists have a new understanding of the pathways that contribute to this gene silencing.
What causes inactivation of an ion channel?
This the first time researchers have identified the mechanism for closed-state inactivation, and the approaches used here could be applied to other ion channels.
Understanding EZH2 inhibitor resistance
St. Jude scientists looked for resistance mechanisms in rhabdoid tumor cells and found the cells require the protein NSD1.
Scientists reveal new cause of cancer
The team looked at a poorly understood form of chronic leukemia, CLPD-NK. The results led the researchers to create a new model of cancer development.
Study shows how a potential new class of antibiotics works
Scientists at St. Jude are studying antimicrobial compounds called argyrins. Argyrins have shown some success against a bacterium called Pseudomonas aeruginosa.
EGFR inhibitors show promise against rhabdomyosarcoma in the lab
Rhabdomyosarcoma is the most common soft tissue tumor in children. When it recurs after therapy, the survival rate is only 30%.
A tale of two tails
St. Jude scientists reveal how GPCR signaling is regulated, with implications for drug development.
“Junk” DNA can cause cancer
Scientists from St. Jude found a novel cause of high-grade glioma, an aggressive pediatric brain cancer.
Vaccination vs. infection: understanding SARS-CoV-2
St. Jude scientists have studied how vaccination before and after COVID-19 infections affect the immune response.
Study has implications for developing universal flu vaccine
St. Jude scientists have found a clue as to why our immune systems do not target virus components that all flu strains share.
Removing barriers to pediatric early warning systems
PEWS are not widely used in hospitals with limited resources. To understand why, scientists at St. Jude conducted a study.
Unique CAR T cell shows promise against AML in the lab
St. Jude scientists have created a targeted strategy for destroying a type of pediatric leukemia using CAR T cells.
How T cells respond to vaccination against COVID-19
Scientists at St. Jude and Washington University School of Medicine in St. Louis are learning how the immune system responds to mRNA vaccination.
Biologic features help cells stay organized
Structural biologists at St. Jude created a model to predict phase separation among proteins in cells.
Phase separation process helps leukemia develop
Scientists at St. Jude have revealed how a process used by cells to organize proteins is essential to the formation of leukemia by fusion oncoproteins.
Understanding the global burden of adolescent cancer
Adolescents are often overlooked in worldwide cancer policy. St. Jude researchers are working with over 700 international colleagues to highlight their needs.
‘Astounding’ results reported for children with high-risk neuroblastoma
The monoclonal antibody called hu14.18K322A is made on the St. Jude campus, and works by attaching to the surface of the tumor and revving up the immune response to kill the tumor cells.
Activating ALK: Ligand binding holds the key
St. Jude Children’s Research Hospital scientists have shed light on the way ligands bind to and activate ALK, an important target for cancer drug development.
Sending neuroblastoma cells to the trash
Scientists at St. Jude and Dana-Farber Cancer Institute created a compound to selectively degrade the EP300 enzyme that neuroblastoma cells need to survive.
Biomarker predicts medulloblastoma relapse
St. Jude scientists developed a test to look for signals that identify the presence of cell-free DNA from medulloblastoma.
Changing tumor cell identity
Scientists at St. Jude and Dana-Farber Cancer Institute learned how retinoic acid changes tumor cells in children with high-risk neuroblastoma.
DNA damage causes neurological syndrome
St. Jude scientists found that a DNA repair system breakdown is to blame for Aicardi-Goutières syndrome (AGS).
Figuring out how T cells interpret signals
St. Jude scientists are studying how cytokines that promote inflammatory responses affect T cells.
Learning from ‘natural gene therapy’
St. Jude scientists worked with researchers in Europe to learn how they might be able to manipulate SAMD9 and SAMD9L genes to the advantage of the patients.
Meet the PANoptosome
St. Jude scientists found that inflammasomes can work with other cell death pathway molecules, resulting in a mega-cell death complex called a PANoptosome.
COVID-19 worse in children with cancer
Scientists at St. Jude and the International Society of Paediatric Oncology created a global registry to study how the COVID-19 pandemic affects children with cancer.
Research tool builds neighborhoods of data
St. Jude scientists created a tool to compare T-cell receptor sequence and gene-expression data.
Every patient’s cancer tells a unique genomic story
St. Jude scientists decoded and analyzed genomic material from both tumors and normal cells to better identify mutations.
Molecular groups give context to clinical results
St. Jude scientists looked at tumor samples from a Children’s Oncology Group clinical trial and assigned participants to molecular groups. The findings changed how the trial’s results were interpreted.
Visualizing moving molecules
St. Jude researchers are trying to visualize and better understand the movements of the ribosome.
A pathway to balance revealed
St. Jude scientists found a metabolic control pathway that regulates how specialized immune cells develop.
Studies show what stressed cells need to recover
St. Jude scientists are trying to understand cell stress responses and how it applies to neurodegenerative diseases.
Finding the genetic driver of a hard-to-classify leukemia
Scientists at St. Jude and the Munich Leukemia Laboratory found a new subtype of leukemia.
Method reveals secrets of drug receptors in cells
Scientists at St. Jude and Columbia University worked together to create a tracking system that can follow drug receptors moving along living cell membranes.
Researchers go deep to understand treatment response
St. Jude scientists analyzed tumor samples from a 10-year clinical trial that studied medulloblastoma.
Collaboration controls killers
Scientists at St. Jude looked at sequences of DNA to determine how they can destroy cancer cells that resist treatment.
Genetic base editing shows promise for treatment of sickle cell disease
St. Jude Children's Research Hospital scientists have helped advance a new therapy for sickle cell disease.
Cost calculation aims to promote discussion about drug prices
A St. Jude analysis found a gap between the cost of manufacturing and distribution for hemophilia B gene therapy.
By age 10, retinoblastoma patients’ learning and life skills rebound
St. Jude researchers found that retinoblastoma survivors functioned within the normal range of learning and life skills after five years.
Signals from muscle protect from dementia
Scientists at St. Jude are studying how signals sent from skeletal muscle affect the brain.
Socioeconomic status plays a major role in cognitive outcomes
St. Jude scientists are studying the risk factors associated with cancer treatments and its effects on cognition.
A genomic map to therapy-related blood cancers
St. Jude scientists are studying mutations that lead to a certain kind of treatment-related blood cancer.
Challenging dogma about a relapsed brain tumor
St. Jude scientists are studying the molecular mechanisms responsible for medulloblastoma treatment failure and recurrence.
Instruments err. This tool identifies the mistakes.
St. Jude scientists created a free mathematical tool to find instrument-caused errors.
COVID-19 poses a serious risk to bone marrow transplant recipients
St. Jude scientists are discovering that children and adults who receive bone marrow transplants should make COVID-19 prevention a priority.
Machine learning gives research a leg up
St. Jude scientists developed deep learning to add to machine learning methods, which helps grow cancer research tools.
What’s to be learned by ‘painting’ the cancer genome? Plenty!
St. Jude scientists helped develop a web-based tool to offer researchers the ability to analyze genomic data.
Results published on medulloblastoma clinical trial
St. Jude researchers find more insight into medulloblastoma molecular groups to determine treatment for patients.
Massive cloud eases genomic data sharing
St. Jude researchers developed a cloud-based, data-sharing platform, which is the world’s largest pediatric cancer genomic data resource.
A fungal infection can kick off inflammation
Scientists have found how A. fumigatus activates the inflammasome.
Researchers offer new strategy to stop COVID-19
St. Jude scientists may have figured out how COID-19 kills and how to stop it.
Researchers look to flu to better understand how the body fights COVID-19
St. Jude scientists teamed up with those at Washington University School of Medicine in St. Louis to compare how the disease-fighting immune system combats the flu and COVID-19.
Why do many drugs work in the lab but fail to get to the clinic?
Researchers identify new forms of membrane proteins that offer drug development targets to minimize medication side effects.
How do neurons develop?
St. Jude researchers are studying the Siah2 protein to determine how brain cells mature.
Protecting the lungs after flu and other respiratory infections
St. Jude researchers have discovered cells that help regulate inflammation.
Ultra-high field NMR device adds to understanding of drug resistance
Scientists at St. Jude used the most powerful NMR device in the United States to study a protein that drives some leukemias.
Study reveals structure of DUOX1 complex
Researchers are learning more about how DUOX1 complex contributes to disease.
Computational tool helps to illuminate hidden mutations
St. Jude researchers developed a powerful tool that can identify cancer-causing mutations in genomes.
CHANGE-Seq tool helps target genome editing
St. Jude scientists create more scalable tools to study genome-editing methods.
Combination therapy holds promise for rare immune disorder
Recent research shows how an overactive immune system produces too many cytokines in HLH.
Predicting secondary cancer risk in childhood cancer survivors
St. Jude scientists are studying the effect of cancer treatments and inherited mutations in DNA-repair genes.
Caspase-8 triggers inflammatory signaling in multiple ways
Beyond its role in cell death, St. Jude scientists have uncovered how caspase-8 contributes to inflammation.
Scientists study how bacteria evolve to resist antibiotics
Researchers at St. Jude contribute to a study of bacteria and its evolving resistance to antibiotics.
Research reveals complexity of phase separation
St. Jude researchers contribute to studying the nucleolus to learn more about phase separation.
Fine tuning phase separation
Studying the interactions between proteins and RNA which define phase separation, St. Jude researchers were able to determine how each protein contributes.
Unraveling the mysteries of caspase-6
St. Jude researchers discovered possible new ways to fight viruses and inflammatory illnesses.
Expanding ways to tame a global childhood killer
A new anti-malarial drug offers hope for children suffering from Malaria.
Inherited mutation can drive SHH medulloblastoma
Researchers find connections to inherited genetic mutations to a type of brain tumor. The study suggests certain genes should be included in routine testing.
The role of oxygen in wiring the brain
Scientists at St. Jude are studying the role oxygen plays in the maturation and migration of neurons and have identified a new mechanism that helps control these processes.
Push to restore leukemia treatment effectiveness gains ground
St. Jude Children’s Research Hospital scientists developed a way to discover the genes responsible for resistance to steroids in leukemia patients.
Obesity linked to severity and longer duration of flu
New research suggests that obesity may be linked to increased severity and longer duration of the flu as well as higher amounts of flu in the body.
Predicting protein phase separation
St. Jude has developed a way to predict how proteins phase separate. The answer will help scientists studying how these proteins contribute to disease.
How MAGE-A11 gene drives cancer revealed
Results show a gene that drives cancer by promoting alternative polyadenylation
Chinese collaboration yields results
St. Jude is working with the Chinese Children’s Cancer Group to lead the first Phase III clinical trial comparing targeted therapies for a high-risk type of leukemia.